CompoAtlas

YouBest Colon Health Aloe & Glucomannan Capsule

Texto original en francés.

Producto de salud natural autorizado en Canadá

Si este producto se vendiera en Francia

Solo se calcula una cantidad diaria para una posología oral explícita para adultos, expresada por día y en una unidad sólida correspondiente a la forma del producto. No se extrapolan las unidades ambiguas, los líquidos, los polvos ni las dosis pediátricas. Una cantidad no calculada no se compara con los límites de dosis. Este análisis no constituye una autorización de venta en Francia ni una evaluación de seguridad o eficacia.

Composición

Ingrediente medicinal y fuentePor unidad posológica, según la fuenteMáximo diario, adulto
Aloe vera

Fuente : Feuille

Potencia : 20 % Hydroxyanthracene derivatives

50 milligrammeNo calculada
Glucomannane

Fuente : Amorphophallus konjac - tubercule

500 milligrammeNo calculada

Ingredientes no medicinales

Carboxyméthylcellulose, Stéarate de magnésium

Dosis recomendadas en Canadá

PoblaciónEdadCantidad por tomaFrecuencia
Adultesminimum : 19 ans2 Capsule1 Tous les jours

Usos autorizados en Canadá

(Aloe latex is traditionally used in Herbal Medicine as a) stimulant laxative.

Texto original en francés.

Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.

Advertencias en Canadá

Effets indésirables connus : Hypersensitivity, such as an allergy, has been known to occur; in which case, discontinue use. If you experience chest pain, vomiting, or difficulty swallowing or breathing after taking the product, seek immediate medical attention. Loose stools, flatulence, diarrhea, and abdominal discomfort have been reported.

Texto original en francés.

Précautions et mises en garde : Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are taking thiazide diuretics, corticosteroids, licorice root or other medications or health products which may aggravate electrolyte imbalance. Consult a health care practitioner prior to use if you have a kidney disorder, or are taking cardiac medications (e.g. cardiac glycosides or antiarrhythmic medications). Consult a health care practitioner prior to use if you have faecal impaction or symptoms such as abdominal pain, nausea, vomiting or fever. Reduce dose or discontinue use if you experience abdominal pain, cramps, spasms and/or diarrhoea. Consult a health care practitioner prior to use if you have diabetes. Do not use if you have difficulty swallowing.

Texto original en francés.

Contre-indications : Do not use if you are pregnant or breastfeeding. Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease (e.g. Crohn's disease or ulcerative colitis), abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes, hemorrhoids or diarrhoea.

Texto original en francés.

Ficha del producto

Otros nombres
Aloe & Glucomannan Capsule, Colon Health Aloe & Glucomannan Capsule, Daily Care Colon Health Aloe & Glucomannan
Titular
Cancap Pharmaceutical Ltd.
NPN o DIN-HM
80086465
Estado
Licencia no activa
Fecha de licencia
21 de junio de 2018
Fecha de revisión
No indicada
Forma
Capsule
Vía de administración
Orale
Tipo de solicitud
Non traditionnelle

Fuente

Ficha oficial de Health Canada, licencia 80086465

Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Texto original en inglés.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Texto original en francés.

La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.

Advertencias oficiales (Health Canada)

Health Canada publica advertencias sobre estos ingredientes:

  • Aloe vera
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    ALOE VERA LEAF GEL - Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Mills and Bone 2005; Bartram 1998).

    Fuentes citadas por Health Canada (3)
    • Bartram T. Bartram's Encyclopedia of Herbal Medicine, 1st edition. London (GB): Robinson Publishing Ltd; 1998.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Se aplica a los productos: providing 2.4 g or more fresh leaf gel, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Huseini et al. 2012; Pizzorno and Murray 2006).

    Fuentes citadas por Health Canada (2)
    • Huseini HF, Kianbakht S, Hajiaghaee R, Dabaghian FH. Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Planta Medica 2012;78(4):311-316. PubMed Ensayo aleatorizado
    • Pizzorno J E, Murray M T. Text Book of Natural Medicine, 3rd edition. St. Louis (MO): Elsevier Churchill Livingstone; 2006.

    Condición de aplicación: Demulcent.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 28 de marzo de 2025

    ALOE - ALOE VERA/ALOE FEROX - Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).

    Fuentes citadas por Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
    • Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).

    Fuentes citadas por Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
    • Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.

    Contraindicaciones

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010).

    Fuentes citadas por Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.

    Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).

    Fuentes citadas por Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
    • Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.

    Reacciones adversas conocidas

    Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2016; Brinker 2010).

    Fuentes citadas por Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf

    Monografía de Health Canada del 28 de marzo de 2025

    ALOE - ALOE VERA Topical

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Reacciones adversas conocidas

    Stop use if hypersensitivity/allergy occurs (Gardner and McGuffin 2013; Brinker 2010).

    Fuentes citadas por Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M. éditeurs. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press; 2013.

    Monografía de Health Canada del 29 de agosto de 2025

  • Glucomannane
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    GLUCOMANNAN

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (FDA 2023).

    Fuentes citadas por Health Canada (1)
    • FDA 2023: United States Food and Drug Administration. Specific Labeling Requirements for Specific Drug Products. Code of Federal Regulations Title 21, Volume 4 (21CFR201.319). Rockville (MD): United States Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2023 December 31]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.319

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (UpToDate 2023; EMA 2013; Chen et al. 2003; Vuksan et al. 2001).

    Fuentes citadas por Health Canada (4)
    • Chen HL, Sheu WH, Tai TS, Liaw YP, Chen YC. 2003. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects—a randomized double-blind trial. Journal of American College of Nutrition 22(1):36-42.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf
    • UpToDate 2023: Wolters Kluwer. [Accessed 2023 December 31]. Available from: https://www.wolterskluwer.com/en/solutions/uptodate
    • Vuksan V, Sievenpiper JL, Xu Z, Wong EYY, Jenkins AL, Beljan-Zdravkovic U, Leiter LA, Josse RG, Stavro M.P. 2001. Konjac-mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. Journal of the American College of Nutrition 20:370S-380S.

    Condición de aplicación: Laxative; Promotion of bowel movement; Constipation relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).

    Fuentes citadas por Health Canada (2)
    • Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
    • Repchinsky C, editor. 2002. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.

    Contraindicaciones

    Condición de aplicación: All products.

    Do not use if you have difficulty swallowing (FDA 2023; Sweetman 2007; Vanderbeek et al. 2007; Henry et al. 1986).

    Fuentes citadas por Health Canada (5)
    • FDA 2023: United States Food and Drug Administration. Specific Labeling Requirements for Specific Drug Products. Code of Federal Regulations Title 21, Volume 4 (21CFR201.319). Rockville (MD): United States Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2023 December 31]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.319
    • Henry DA, Mitchell AS, Aylward J. 1986. Glucomannan and risk of esophageal obstruction. British Medical Journal 292:591-592.
    • Sweetman SC, editor. 2007. Martindale: The Complete Drug Reference, 35th edition. London (GB): Pharmaceutical Press.
    • Vanderbeek PB, Fasano C, O'Malley G, Hornstein J. 2007. Esophageal obstruction from a pharmacobezoar containing glucomannan. Clinical Toxicology 45(1):80-82.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Consulté le 31 décembre 2023]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2013; Pray 2006; Berardi et al. 2002).

    Fuentes citadas por Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf
    • Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2013).

    Fuentes citadas por Health Canada (1)
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf

    When using this product you may experience temporary gas and bloating (Sood et al. 2008).

    Fuentes citadas por Health Canada (1)
    • Sood N, Baker WL, Coleman CI. 2008. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. American Journal of Clinical Nutrition 88(4):1167-1175.

    Monografía de Health Canada del 26 de julio de 2024

Se refieren al ingrediente, no a este producto ni a su dosis. No sustituyen el consejo médico.

Se desconoce la fecha de la prueba de esta lista de ingredientes.

¿Ha cambiado el producto? Fotografíe el envase.

¿Alguna información inexacta o más reciente sobre este producto, sea usted lector o marca? Escriba a contact@compoatlas.com: cada corrección se publica en el registro de correcciones.

Intro para analizar, Mayús+Intro para una nueva línea